General Information of Drug Off-Target (DOT) (ID: OT1P06NV)

DOT Name Serine/threonine-protein kinase TBK1 (TBK1)
Synonyms EC 2.7.11.1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1
Gene Name TBK1
Related Disease
Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 ( )
Frontotemporal dementia with motor neuron disease ( )
Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 8 ( )
UniProt ID
TBK1_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
4EFO; 4EUT; 4EUU; 4IM0; 4IM2; 4IM3; 4IW0; 4IWO; 4IWP; 4IWQ; 5EOA; 5EOF; 5EP6; 5W5V; 6BNY; 6BOD; 6BOE; 6CQ0; 6CQ4; 6CQ5; 6NT9; 6O8B; 6RSR; 6RST; 6RSU
EC Number
2.7.11.1
Pfam ID
PF00069 ; PF18394 ; PF18396
Sequence
MQSTSNHLWLLSDILGQGATANVFRGRHKKTGDLFAIKVFNNISFLRPVDVQMREFEVLK
KLNHKNIVKLFAIEEETTTRHKVLIMEFCPCGSLYTVLEEPSNAYGLPESEFLIVLRDVV
GGMNHLRENGIVHRDIKPGNIMRVIGEDGQSVYKLTDFGAARELEDDEQFVSLYGTEEYL
HPDMYERAVLRKDHQKKYGATVDLWSIGVTFYHAATGSLPFRPFEGPRRNKEVMYKIITG
KPSGAISGVQKAENGPIDWSGDMPVSCSLSRGLQVLLTPVLANILEADQEKCWGFDQFFA
ETSDILHRMVIHVFSLQQMTAHKIYIHSYNTATIFHELVYKQTKIISSNQELIYEGRRLV
LEPGRLAQHFPKTTEENPIFVVSREPLNTIGLIYEKISLPKVHPRYDLDGDASMAKAITG
VVCYACRIASTLLLYQELMRKGIRWLIELIKDDYNETVHKKTEVVITLDFCIRNIEKTVK
VYEKLMKINLEAAELGEISDIHTKLLRLSSSQGTIETSLQDIDSRLSPGGSLADAWAHQE
GTHPKDRNVEKLQVLLNCMTEIYYQFKKDKAERRLAYNEEQIHKFDKQKLYYHATKAMTH
FTDECVKKYEAFLNKSEEWIRKMLHLRKQLLSLTNQCFDIEEEVSKYQEYTNELQETLPQ
KMFTASSGIKHTMTPIYPSSNTLVEMTLGMKKLKEEMEGVVKELAENNHILERFGSLTMD
GGLRNVDCL
Function
Serine/threonine kinase that plays an essential role in regulating inflammatory responses to foreign agents. Following activation of toll-like receptors by viral or bacterial components, associates with TRAF3 and TANK and phosphorylates interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRFs leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNA and IFNB. In order to establish such an antiviral state, TBK1 form several different complexes whose composition depends on the type of cell and cellular stimuli. Plays a key role in IRF3 activation: acts by first phosphorylating innate adapter proteins MAVS, STING1 and TICAM1 on their pLxIS motif, leading to recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1. Phosphorylated IRF3 dissociates from the adapter proteins, dimerizes, and then enters the nucleus to induce expression of interferons. Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing-complexes. Under particular conditions, functions as a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus. Restricts bacterial proliferation by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', thus enhancing LC3 binding affinity and antibacterial autophagy. Phosphorylates SMCR8 component of the C9orf72-SMCR8 complex, promoting autophagosome maturation. Phosphorylates ATG8 proteins MAP1LC3C and GABARAPL2, thereby preventing their delipidation and premature removal from nascent autophagosomes. Phosphorylates and activates AKT1. Seems to play a role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity. Attenuates retroviral budding by phosphorylating the endosomal sorting complex required for transport-I (ESCRT-I) subunit VPS37C. Phosphorylates Borna disease virus (BDV) P protein. Plays an essential role in the TLR3- and IFN-dependent control of herpes virus HSV-1 and HSV-2 infections in the central nervous system. Acts both as a positive and negative regulator of the mTORC1 complex, depending on the context: activates mTORC1 in response to growth factors by catalyzing phosphorylation of MTOR, while it limits the mTORC1 complex by promoting phosphorylation of RPTOR.
Tissue Specificity Ubiquitous with higher expression in testis. Expressed in the ganglion cells, nerve fiber layer and microvasculature of the retina.
KEGG Pathway
Ras sig.ling pathway (hsa04014 )
Mitophagy - animal (hsa04137 )
Autophagy - animal (hsa04140 )
Toll-like receptor sig.ling pathway (hsa04620 )
NOD-like receptor sig.ling pathway (hsa04621 )
RIG-I-like receptor sig.ling pathway (hsa04622 )
Cytosolic D.-sensing pathway (hsa04623 )
IL-17 sig.ling pathway (hsa04657 )
Alcoholic liver disease (hsa04936 )
Amyotrophic lateral sclerosis (hsa05014 )
Pathways of neurodegeneration - multiple diseases (hsa05022 )
Shigellosis (hsa05131 )
Yersinia infection (hsa05135 )
Hepatitis C (hsa05160 )
Hepatitis B (hsa05161 )
Measles (hsa05162 )
Human cytomegalovirus infection (hsa05163 )
Influenza A (hsa05164 )
Human papillomavirus infection (hsa05165 )
Kaposi sarcoma-associated herpesvirus infection (hsa05167 )
Herpes simplex virus 1 infection (hsa05168 )
Epstein-Barr virus infection (hsa05169 )
Human immunodeficiency virus 1 infection (hsa05170 )
Coro.virus disease - COVID-19 (hsa05171 )
Lipid and atherosclerosis (hsa05417 )
Reactome Pathway
DDX58/IFIH1-mediated induction of interferon-alpha/beta (R-HSA-168928 )
Regulation of innate immune responses to cytosolic DNA (R-HSA-3134975 )
STAT6-mediated induction of chemokines (R-HSA-3249367 )
IRF3-mediated induction of type I IFN (R-HSA-3270619 )
TNFR1-induced proapoptotic signaling (R-HSA-5357786 )
Regulation of TNFR1 signaling (R-HSA-5357905 )
Interleukin-37 signaling (R-HSA-9008059 )
TICAM1-dependent activation of IRF3/IRF7 (R-HSA-9013973 )
TRAF3-dependent IRF activation pathway (R-HSA-918233 )
TRAF6 mediated IRF7 activation (R-HSA-933541 )
Negative regulators of DDX58/IFIH1 signaling (R-HSA-936440 )
Activation of IRF3, IRF7 mediated by TBK1, IKK (IKBKE) (R-HSA-936964 )
Potential therapeutics for SARS (R-HSA-9679191 )
SARS-CoV-1 activates/modulates innate immune responses (R-HSA-9692916 )
SARS-CoV-2 activates/modulates innate and adaptive immune responses (R-HSA-9705671 )
IRF3 mediated activation of type 1 IFN (R-HSA-1606341 )

Molecular Interaction Atlas (MIA) of This DOT

3 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 DISYI9SD Definitive Autosomal dominant [1]
Frontotemporal dementia with motor neuron disease DISPZM6A Supportive Autosomal dominant [2]
Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 8 DISAG9IO Limited Autosomal dominant [3]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
16 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [4]
Tretinoin DM49DUI Approved Tretinoin increases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [5]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [6]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate increases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [7]
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [8]
Quercetin DM3NC4M Approved Quercetin decreases the activity of Serine/threonine-protein kinase TBK1 (TBK1). [9]
Sulindac DM2QHZU Approved Sulindac increases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [10]
Diphenylpyraline DMW4X37 Approved Diphenylpyraline decreases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [11]
Amlexanox DM0DQM5 Approved Amlexanox decreases the activity of Serine/threonine-protein kinase TBK1 (TBK1). [12]
Flavonoid derivative 1 DMCQP0B Patented Flavonoid derivative 1 decreases the activity of Serine/threonine-protein kinase TBK1 (TBK1). [9]
Formaldehyde DM7Q6M0 Investigative Formaldehyde decreases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [14]
Glyphosate DM0AFY7 Investigative Glyphosate decreases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [15]
Chrysin DM7V2LG Investigative Chrysin decreases the activity of Serine/threonine-protein kinase TBK1 (TBK1). [9]
OXYBENZONE DMMZYX6 Investigative OXYBENZONE increases the expression of Serine/threonine-protein kinase TBK1 (TBK1). [16]
ERIODICTYOL DMD3BEQ Investigative ERIODICTYOL decreases the activity of Serine/threonine-protein kinase TBK1 (TBK1). [9]
BX-795 DMRIMLJ Investigative BX-795 decreases the activity of Serine/threonine-protein kinase TBK1 (TBK1). [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Drug(s)
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
PMID28870136-Compound-52 DMFDERP Patented PMID28870136-Compound-52 increases the phosphorylation of Serine/threonine-protein kinase TBK1 (TBK1). [13]
------------------------------------------------------------------------------------

References

1 Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
2 Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015 May;18(5):631-6. doi: 10.1038/nn.4000. Epub 2015 Mar 24.
3 Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med. 2012 Aug 27;209(9):1567-82. doi: 10.1084/jem.20111316. Epub 2012 Jul 30.
4 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
5 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
6 Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
7 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
8 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
9 Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. Biochem Pharmacol. 2009 Apr 15;77(8):1391-400. doi: 10.1016/j.bcp.2009.01.009. Epub 2009 Jan 23.
10 Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
11 Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers. J Allergy Clin Immunol. 2016 Dec;138(6):1690-1700. doi: 10.1016/j.jaci.2016.02.038. Epub 2016 Apr 24.
12 Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015 Mar;35(3):143-56. doi: 10.1089/jir.2014.0038. Epub 2014 Oct 16.
13 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
14 Gene expression changes in primary human nasal epithelial cells exposed to formaldehyde in vitro. Toxicol Lett. 2010 Oct 5;198(2):289-95.
15 Glyphosate-based herbicides at low doses affect canonical pathways in estrogen positive and negative breast cancer cell lines. PLoS One. 2019 Jul 11;14(7):e0219610. doi: 10.1371/journal.pone.0219610. eCollection 2019.
16 Chromatin modifiers: A new class of pollutants with potential epigenetic effects revealed by in vitro assays and transcriptomic analyses. Toxicology. 2023 Jan 15;484:153413. doi: 10.1016/j.tox.2022.153413. Epub 2022 Dec 26.